Endevia Bio, based in Chicago, USA, is a pharmaceutical company that is developing TCMCB07, a novel synthetic peptide product for the potential treatment of cachexia. This has the potential to create a new standard of care for millions of patients who develop cachexia every year.
This molecule was an ideal candidate for Quotient Sciences’ integrated Translational Pharmaceutics® platform. In our case study, Russell Potterfield, CEO of Endevica Bio, explains how Quotient Sciences has supported their business with an integrated formulation development and Phase I clinical study program, accelerating the development of TCMCB07, and saving costs in the process.
Request a copy of our case study today and contact us to find out how we can accelerate drug development timelines saving as much as 12 months in the process with our Translational Pharmaceutics® platform.
"If someone were to ask if I would work with Quotient Sciences again, I’d give them two thumbs up all the way. As a start-up biotech you cannot underestimate how difficult it is to find the right outsourcing partner. You must have a partner that is going to be able to help you through the hard stuff and helps save you as much money as possible."
- Russell Potterfield, CEO of Endevica Bio at Endevica Bio